Alterity Therapeutics Files 6-K, Incorporates Half-Yearly Report
Ticker: PRNAF · Form: 6-K · Filed: Feb 29, 2024 · CIK: 1131343
| Field | Detail |
|---|---|
| Company | Alterity Therapeutics Ltd (PRNAF) |
| Form Type | 6-K |
| Filed Date | Feb 29, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, half-yearly-report, foreign-issuer
TL;DR
**Alterity Therapeutics just filed a 6-K with their Half Yearly Report, so check it for updates.**
AI Summary
Alterity Therapeutics Limited, a foreign private issuer, filed a 6-K report on February 29, 2024, for the month of February 2024. This filing incorporates by reference into several of its Registration Statements on Form S-8 (Files No. 333-251073, 333-248980, and 333-228671) and Form F-3 (Files No. 333-274816, 333-251647, 333-231417, and 333-250076). The key exhibit submitted was the Half Yearly Report and Accounts.
Why It Matters
This filing provides transparency on Alterity Therapeutics' financial and operational status through its Half Yearly Report and Accounts, which is crucial for investors assessing the company's performance.
Risk Assessment
Risk Level: low — This is a routine filing for a foreign private issuer and does not inherently indicate new risks, but rather provides updated information.
Key Players & Entities
- Alterity Therapeutics Limited (company) — Registrant
- February 2024 (date) — Period of Report
- February 29, 2024 (date) — Filing Date
- 333-251073 (dollar_amount) — Form S-8 File Number
- 333-274816 (dollar_amount) — Form F-3 File Number
FAQ
What type of report did Alterity Therapeutics Limited file?
Alterity Therapeutics Limited filed a Form 6-K, which is a Report of Foreign Private Issuer.
When was this 6-K report filed?
The 6-K report was filed on February 29, 2024.
What is the primary exhibit submitted with this 6-K filing?
The primary exhibit submitted with this 6-K filing is the Half Yearly Report and Accounts.
Into which registration statements is this 6-K being incorporated by reference?
This 6-K is being incorporated by reference into Registration Statements on Form S-8 (Files No. 333-251073, 333-248980, and 333-228671) and Form F-3 (Files No. 333-274816, 333-251647, 333-231417, and 333-250076).
What is the business address of Alterity Therapeutics Limited as stated in the filing?
The business address of Alterity Therapeutics Limited is Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia.
Filing Stats: 190 words · 1 min read · ~1 pages · Grade level 11.8 · Accepted 2024-02-28 17:46:06
Filing Documents
- ea0200858-6k_alterity.htm (6-K) — 14KB
- ea0200858ex99-1_alterity.htm (EX-99.1) — 335KB
- ex99-1_001.jpg (GRAPHIC) — 342KB
- ex99-1_002.jpg (GRAPHIC) — 2KB
- 0001213900-24-018145.txt ( ) — 823KB
From the Filing
OF FOREIGN PRIVATE ISSUER SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2024 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073 , 333-248980 and 333-228671 ) and our Registration Statements on Form F-3 (Files No. 333-274816 , 333-251647 , 333-231417 and 333-250076 ) ALTERITY THERAPEUTICS LIMITED (a development stage enterprise) The following exhibits are submitted: 99.1 Half Yearly Report and Accounts 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Alterity Therapeutics Limited By: /s/ Geoffrey P. Kempler Geoffrey P. Kempler Chairman Date: February 28 , 2024 2